John Winkelman, MD, PhD

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital talked about the new clinical guidelines for treating restless legs syndrome which emphasize the risks of dopamine agonists and advocate for alternative therapies. [WATCH TIME: 8 minutes]

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital discussed the newly updated treatment guidelines for the treatment of restless legs syndrome.

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital provided perspective on the current major research priorities for the treatment of restless legs syndrome. [WATCH TIME: 3 minutes]

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital discussed the benefits opioids have for patients with restless legs syndrome, as well as how they can be safely used as part of treatment strategies. [WATCH TIME: 4 minutes]

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital provided insight on new updates to the management of restless legs syndrome, including removing dopamine agonists as first line treatments. [WATCH TIME: 8 minutes]